Post-operative Radiation Therapy for esophageal Cancer; Study of Failure Pattern

Mi Sook Kim, M.D., Jae Young Kim, M.D., Seoung Yul Yoo, M.D. Hyung Jun Yoo, M.D., Jae III Zo, M.D.*, Hee Jong Baek, M.D.* Jong Ho Park, M.D.*

Department of Radiation Oncology, Thoracic Surgery*, Korea Cancer Center Hospital, Seoul, Korea

<u>Purpose</u>: This study evaluated the survival, local control, prognostic factor, and failure pattern of patients with esophageal cancer treated with operation and adjuvant radiation therapy to use as fundermental data of postoperative radiation therapy.

<u>Materials and Methods</u>: A retrospective analysis was undertaken of 82 patients who had locally advanced esophageal cancer treated with operation and adjuvant radiation therapy from January 1988 to December 1995. According to AJCC staging, stage IIA were in 26 patients, stage IIB in 4 patients, and stage III in 52 patients. Squamous cell carcinoma were in 77 patients, adenosquamous carcinoma in 3 patients, and adenocarcinoma in 2 patients. The patients received radiation therapy ranging from 41 Gy to 64.8 Gy. Five patients received neoadjuvant chemotherapy.

Results: Two-year survival and local control rates for all patients were 36.8% and 30.4% respectively. And they were 9.3% and 26.3% respectively at 5 years. According to stages, 2-year survival rates were 50.2% in IIA, 0% in IIB and 23.3% in III(p=0.004). Two-year local control rates were 49.2% in IIA, 66.6% in IIB and 24.7% in III(p=0.01). Sixty patients developed recurrence, which were 3 tumor margin, 23 lymph node recurrence, 4 tumor margin and lymph node, 1 tumor margin and distant metastasis, 9 lymph node and distant metastasis, 17 distant metastasis and 3 unknown metastatic site. Prognostic factors affecting survival were smoking (p=0.02), Tstaging(p=0.0092), Nstaging(p=0.0045). Prognostic factors affecting local control were T-staging(p=0.019), N-staging(p=0.047).

<u>Conclusion</u>: In spite of post-operative radiation therapy, predominant failure pattern was local failure. Especially regional lymph node failure was major cause of local failure. So strategy of aggresive adjuvant radiation therapy to regional lymph node area in post operative treatment should be proposed.

Key Words: Esophageal cancer, Operation, Radiation Therapy, Failure pattern

98 1998 6 4 1998 8 28 . : ,

```
1988 1 1995 12
                                               40 Gy
                                                                     가
                                                                     가 81 ,
                                          가 1
                            가
                                                                    73
                                                              42
                                                         1997 American Joint
                                       Committee on Cancer (AJCC) TNM
                       가
                                        . A가 26 , B가 4 , 가 52
              . 1980
                      Earlam
                              Cunha-
Melo
                                       Adenosquamous 3 , 2 .
                                       AJCC
                                        , ,
                  가
                                                                    가 가
                                                             Ivor
                                                                  Lewis
            4±3%
                                       (Abdominal incision,
                                                           right
                                                                  thoracotomy,
                             6±6%
                                       esophagogastrostomy)
                가
                                                  5 microtron
                                                                 6 MV
                                                                          10
                    85.7%,
                                                       1.8 Gy
Ш
                                       MV X-ray
                                                                  2.0 Gy
            34.1%
                    15.2%
                                              41.0 Gy 64.8 Gy
                                              ( 50.4 Gy).
     가
                              (serosa)
                                                       5 cm
                                                                    9 cm
가
      가
                               가
                                              2
                                                      41 Gy 45 Gy
                                                  (anterior and posterior oblique port)
           가
                                                              PEF (cisplatin,
                           Teniere
                                       ectoposide, 5-FU)
                 가
7%
                     가
                               38%
                                       2 .
            가
                      가
                                                                   가
```

(simulation film)

3

Meier Log-rank test

2 2 36.8 30.4% 9.3% 26.2% (Fig. 1). 2 A가 50.2%, IIB가 0%, 가 23.3% (p=0.004),28.2 , 15.3 , 12.4 (Fig. 2). 2 IIA가 49.2%, IIB가 66.6%, III가 24.7% (p=0.01)(Fig. 3). 73.2% 60 3 , 23 , 가 가 1 가 9 , 가 17 . (Table 1) 3 8 , 27 36 가





Fig. 1. Overall survival and locoregional control.








Fig. 3. Local control by stage for esophageal cancer.

Table 1. Patterns of Failure

Recurred Site	No. of pts
Locoregional Only Primary site Regional lymph node Primary site + regional lymph node	30 (36.5%) 3 23 4
Locoregional + DM (distant metastasis) Primary site + DM Regional lymph node + DM	10 (12.2%) 1 9
Distant Metastasis Only	17 (20.7%)
Unknown Site	3 (3.6%)
Total	60 (73 %)

I alabie 2.Programment e acatore Attending coo air want rol

Prograstic factors	No.Nov6ptsafpts	MS*	1-YSR*	(1987)SR [†] (%))3-Y 3 RY8%R) [†] (%)	<i>p</i> -yækuædue
Age Age≤ 50	. 8		43.8		0 0	0.17 ^{0.99}
<5 5 0-59 50-580 Diet 60	8 40 40 34 34	11 19 17	67.3 68.0	25.0 74.0 69.2	40.3 0 24.2 25.9 24.2 0.87	0.270.48
Dießeneral Getheral Weitneht Loss	20 19 60 60	17 17	51.2 69.1	65.0 68.3	0 32.8 15.0 17.8	0.850.73
WeYgefstLoss Yolss ⊤Nobacco	43 43 29 29	17 18	64.6 64.8	64.4 74.0	28.7 39.6 54.7 18.5	0.02 0.
ToMasco YeNo AloNomol	19 19 61 61	19 17	72.0 62.0	66.6 66.2	40.0 28.4 33.2 10.8	0.39 _{0.27}
Alco Yies Yntes Lotstation	16 16 66 66	17 17	56.3 68.2	75.0 64.9	24.1 31.4 25.6 14.6	0.27
Locatienvical Cenvieral horax Univer Tonavax Nikoweno Taxorax	8 8 6 6 54 54 14	17 20 17	62.5 55.6 64.4 73.9	75.0 60.0 65.1	0 27.8 0 32.1 0 42.2 19.4	0.47
T stage r Thorax Postbb tumor size T24 cm 438 cm	14 1 16 7 61 53	17 21 15	100 50.0 73.3	71.4 86.7 62.4	0.019 29.7 100 25.0 0 35.7 20.5	0.763
∓48 cm TNstatagee TN0	1 33	24 22	43.9 80.1	60.0	17.6 ₀ 44.8	0.047.0092
TN1 Raßation therapy dose T4 45 Gy N-stages Gy	7 49 53 21 9 73	15 19 9	54.0 50.0 66.7	100 74.3 38.1	14.9 20.0 25.0 30.6 20.0 21.6 4.8	0.84
N-Slages Gy NO N1 RT dose	73 33 49	21 3	00.7	83.3 56.1	30.6 30.9 5.7	0.0045
*yea 45 \$ @y ival rate > 45 Gy	9 73	11 17		33.3 71.3	11.1 17.3	0.52

^{*} Median survival, † year survival rate

가 1 , 가 1 . (carina) . Earlam Chunha-1979 20 83,783 가 Melo^{1, 2)} (p=0.02), T 1960 (p=0.0092), N (p=0.0045)가 29%, 5 1 18%, 4% 58%, 가 39%, 가 (Table 2). T (p=0.019) N (p=0.047) 가 가 2% 가 (Table 3). , 2 9%, 5 가 . 5% 10-27% I-II 68% Ш 15-28% 85%, 3, 6-10)

```
Ш
                                                                                                 가
                                             2
          5
                            36.8%
                                     9.3%
                                                                                               5
                                                     30.4%
                                                                26.3%
                                                             가
                                                             60
                                                                                           가
                                                        36.5% 30 ,
                                                                                                 가
                          11)
               Pearson
                                                              12.2%
                                                                       10
     100
                  20%
                                                          48.7%
                                                                                      32.7%
          80%
                                    35%
            가
    가
                                                                 15-18)
                                                                          40%
                                                                                     65%
                                      가
                                                     가
                                                           15-19)
                                                                      15
                                                                               40%
                                     가
                                                                        36.5%
                                                                         . Wu
                                                                가 30%
             가
                                       . Kasai
 12)
                가
                                                                가 8 ,
                                                                                                가 36
  가
                      가
                                                              가
                                                                                         . Yamana
                               가
                                        . Druker
                                                     <sup>21)</sup>, Akakura <sup>22)</sup>
                                                                           LaRoux
  13)
                                        3
                                                     (anastomotic failure),
                                                                                            (tumor bed
      5
                        20%
                               5%
                                                                                         10- 30%
                                                     failure), paraesophageal node
                                       5
                         3
                                                                   . Wong <sup>24)</sup>
        20%
                 0%
                                     . Phase III
                                                     5-10%
                                                                  6 cm
study
         Teniere
                                                                      . Ozawa
                                                                                      Kasai
                                                                                        22%
                                                                                                 44%
                      가
                                                     70-90%
                               Phase III study
                                                                          가
Fok
                     Teniere
                                                       15, 16)
                                     Intrathoracic
recurrence
                                                                 가
                                                                               가
                   가
                                        가
                                      가
                                                                          (tumor bed)
                                                                                                     5
                                                     cm
                                                                                             가
       가
                                                          (carina)
```

 Earlam R, Cunha-Melo JR. Oesophageal squamous cell carcinoma I:A critical review of surgery. Br J Surg 1980; 67:381-340

가

가

- Earlam R, Cunha-Melo JR. Oesophageal squamous cell carcinoma II:A critical review of radiotherapy. Br J Surg 1980; 67:457-461
- King RM, Pairloero PC, Trastek VF. Ivor Lewis esophagogastrectomy for carcinoma of the esophagus:early and late functional results. Ann

- Thorac Surg 1987; 44:119-122
- 4. Teniere P, Hay JM, Fingerhurt A, et al. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. Gynecol Obstet 1991:173:123-130
- 5. Shahian OM, Neptune WB, Ellis FH, et al. Transthoracic versus extrathoracic esophagectomy: Mortality, morbidity and long-term survival. Ann Thorac Sutg 1986; 41:237-246
- Roth JA, Putnam JB. Surgery for cancer of the esophagus. Sem Oncol 1994;21:453-461
- Mathisen DJ, Grillo HC, Wikins EWJ, et al. Transthoracic esophagectomy: A safe approach to carcinoma of the esophagus. Ann Thorac Surg 1988; 45:137-143
- Shao L, Gao Z Yang N, et al. Results of surgical treatment in 6,123 cases of carcinoma of the esophagus and gastric cardia. J Surg Oncol 1989; 42:170-174
- Lozac'h P, Topart P, Etienne J, et al. Ivor Lewis operation for epidermoid carcinoma of the esophagus. Ann Thorac Surg 1991; 52:1154-1157
- 10. Mitchell RL. Abdominal and right thoracotomy approach as standard procedure for esophagogastrectomy with low morbidity. J Thorac Cardiovascu Surg 1987; 93:205-211
- Pearson JG. The present status and future potential of radiotherapy in the management of esophageal cncer. Cancer 1977; 39:882-892
- Kasai M, Mori S, Watanabe T. Follow -up results after resection of thoracic resection of thoracic esophageal cancer. World J Surg 1978; 2:543-551
- **13. Druker MH, Mansour KA, Hatcher CJ, et al.**Esophageal carcinoma : An aggressive approach.
 Ann Thorac Surg 1979; 28:133-138
- **14. Fok M, Sham STS, Choy D, et al.** Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. Surgery 1993; 113:138-147
- Mandard AM, Chasle J, Marnay J, et al. Autopsy findings in 111 cases of esophageal cancer. Cancer 1981; 48:329-335
- 16. Anderson LL. Lad TE. Autopsy findings in squamous cell carcinoma of the esophagus, Cancer 1982; 50:1587-1590
- 17. Bosch A, Frias Z, Caldwell WL, et al. Autopsy findings in carcinoma of the esophagus. Acta Radiol Oncol 1979; 18:103-112
- Raven RW. Carcinoma of the esophagus. A clinicopathologic study. Br J Surg 1948; 36:70-73
- 19. Appleqvist P. Carcinoma of the esophagus and

= =

: 1988 1995 12 40 Gy 82 A가 26, B가 4 가 52 77 , Adenosquamous 3 , 41 Gy 64.8 Gy (50.4 Gy) . 5 **PFC** 2 36.8% 30.4% 5 5 9.3% 26.3% 2 A가 50.2%, IIB가 0%, 가 23.3% (p=0.004). 2IIA가 49.2%, IIB가 66.6%, III가 24.7% (p=0.01) 73.2% 3 23 가 4 , 17 . 3 (p=0.02), T (p=0.0092), N(p=0.0045)가 Т (p=0.019), N(p=0.047)가 가

gastric cardia at autopsy in Findland. Ann Clin Res 1975; 7:334-340

- 20. Wu YK, Chen PT, Fang JP, et al. Surgical treatment of esophageal carcinoma. Am J Surg 1980; 139:18-24
- 21. Yamana H. Pattern of initial recurrence after radical surgery. Presented at US-Japan esophageal carcinoma summit, Honolulu. HA, February, 1993
- **22. Akakura I, Nakamura Y, Kakegawa T, et al.** Surgery of carcinoma of the esophagus with preoperative radiation. Chest 1970; 57:47-51
- 23. LeRoux BT. The influence of resection on the natural history of carcinoma of the hypopharyns, esophagus and proximal stomach. Surg Gynecol Obstet 1962; 115:162-169
- 24. Wong J. Esophageal resection for cancer: The nationale of current practice. Am J Surg 1987; 153: 18-24
- 25. Ozawa S, Ando N, Ueda M, et al. Genetic change of esophageal cancer and a new treatment strategy. Presented at US-Japan esophageal Carcinoma

summit, Honolulu. HA, February, 1993

26. Hussey DH, Barakley T, Bloedorn F. Carcinoma of the esophagus. In :Flecher GH, ed. Textbook of Radiotherapy. 3rd ed. Philadelphia, Lea & Febiger Co. 1980:688-697